13. Vestergaard 2006 (2008b): fracture and DMPA use.
| Subgroup | Cases (N) | Controls (N) | ORa (95% CI) | |
| DMPAb use ever | ‐ | 58 | 105 | 1.44 (1.01 to 2.06) |
| Age of woman (years) |
< 25 | 15 | 29 | 1.20 (0.59 to 2.45) |
| 25 to 50 | 25 | 51 | 1.09 (0.64 to 1.85) | |
| > 50 | 18 | 25 | 2.25 (1.14 to 4.42) | |
| Average daily DMPA dosec |
< 0.25 | 21 | 32 | 1.73 (0.96 to 3.09) |
| 0.26 to 0.99 | 13 | 38 | 0.88 (0.45 to 1.74) | |
| > 1 | 24 | 35 | 1.94 (1.09 to 3.45) | |
| Duration of DMPA use (years) |
< 2.5 | 16 | 45 | 0.82 (0.43 to 1.56) |
| 2.6 to 4 | 9 | 20 | 1.51 (0.66 to 3.46) | |
| > 4 | 33 | 40 | 2.16 (1.32 to 3.53) | |
aAdjusted for prior fracture, Charlson index (comorbidities), income, working status, living with someone or not, pregnancy, IUD use, hysterectomy, alcoholism; use of OC, corticosteroid, hormonal replacement therapy, anti‐epileptic drugs, and strong (morphine and opioid agonists) and weak analgesics (acetaminophen, nonsteroidal anti‐inflammatory drugs, and acetylsalicylic acid). bDMPA = depot medroxyprogesterone acetate cExposure as average daily dose, i.e., redeemed prescriptions/time from first prescription to fracture or censoring (Characteristics of included studies); < 1 indicates < regular use; > 1 suggests lost prescription and obtained new one.